Aaron Mitschke
Family · Liberty, MENPI 1831450063
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 26.7% of the total. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$952
- Lilly USA, LLC$413
- AstraZeneca$296
- Pfizer$279
- Novo Nordisk$259
- GSK$200
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,553100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $952 |
| Lilly USA, LLC | 25 | $413 |
| AstraZeneca | 19 | $296 |
| Pfizer | 15 | $279 |
| Novo Nordisk | 15 | $259 |
| GSK | 10 | $200 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Exact Sciences | 4 | $78 |
| Dexcom, Inc. | 5 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| Eisai Inc. | 5 | $66 |
| Sumitomo Pharma America, Inc. | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Abbott | 2 | $44 |
| Johnson & Johnson | 3 | $42 |
| Novartis | 2 | $40 |
| Renalytix AI, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Bayer | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Boston Scientific | 1 | $28 |
| Globus Medical | 1 | $22 |
| Amgen | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $19 |
| Medtronic | 1 | $19 |
| Mycovia Pharmaceuticals, Inc. | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $18 |
| Abiomed | 1 | $18 |
| Smith+Nephew | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
How this compares
$3,565 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $130,733 |
| MounjaroTirzepatide | 55 | $75,346 |
| EliquisApixaban | 51 | $52,325 |
| JardianceEmpagliflozin | 54 | $49,957 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $43,001 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $36,105 |
| MyrbetriqMirabegron | 66 | $36,061 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,741 |
| LinzessLinaclotide | 37 | $32,443 |
| TrulicityDulaglutide | 19 | $21,163 |
| GemtesaVibegron | 26 | $18,572 |
| XareltoRivaroxaban | 16 | $15,750 |
| NovologInsulin Aspart | 11 | $6,896 |
| Novolog FlexpenInsulin Aspart | 25 | $4,475 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $4,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $259 | $137,629101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $413 | $96,50974 claims |
| PfizerEliquis | $279 | $52,32551 claims |
| AstraZenecaBreztri Aerosphere | $296 | $43,00141 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $36,06166 claims |
| GSKTrelegy Ellipta | $200 | $32,74137 claims |
| AbbVieLinzess | $952 | $32,44337 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $62 | $18,57226 claims |
| Johnson & JohnsonXarelto | $42 | $15,75016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Liberty
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
- Kristen Schroeder-CyrBrunswick$5K
- Liana KellyBrunswick$5K
- Natalie BubierLewiston$5K
- Holly JamesYork$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.